1.Feine U, Lietzenmayer R, Hanke JP, Held J, Wöhrle H, Müller-Schauenburg W. Fluorine–18-FDG and iodine–131-iodide uptake in thyroid cancer. Journal of Nuclear Medicine. 1996;37(9):1468–72.
2.Schlumberger M, Brose M, Elisei R, Leboulleux S, Luster M, Pitoia F, et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. The lancet Diabetes & endocrinology. 2014;2(5):356–8.
3.Rivera M, Ghossein RA, Schoder H, Gomez D, Larson SM, Tuttle RM. Histopathologic characterization of radioactive iodine‐refractory fluorodeoxyglucose‐positron emission tomography‐positive thyroid carcinoma. Cancer. 2008;113(1):48–56.
4.Wang W, Macapinlac H, Larson SM, Yeh SDJ, Akhurst T, Finn RD, et al. [18F]–2-Fluoro–2-Deoxy-d-Glucose Positron Emission Tomography Localizes Residual Thyroid Cancer in Patients with Negative Diagnostic 131I Whole Body Scans and Elevated Serum Thyroglobulin Levels. The Journal of Clinical Endocrinology & Metabolism. 1999;84(7):2291–302.
5.Xing M. BRAF mutation in thyroid cancer. Endocrine-related cancer. 2005;12(2):245–62.
6.Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocrine reviews. 2007;28(7):742–62.
7.Nagarajah J, Ho AL, Tuttle RM, Weber WA, Grewal RK. Correlation of BRAFV600E mutation and glucose metabolism in thyroid cancer patients: an 18F-FDG PET study. Journal of nuclear medicine. 2015;56(5):662.
8.Agrawal N, Akbani R, Aksoy BA, Ally A, Arachchi H, Asa SL, et al. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3):676–90.
9.Mamede M, Higashi T, Kitaichi M, Ishizu K, Ishimori T, Nakamoto Y, et al. [18F] FDG uptake and PCNA, Glut–1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia. 2005;7(4):369–79.
10.Haberkorn U, Ziegler SI, Oberdorfer F, Trojan H, Haag D, Peschke P, et al. FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models. Nuclear medicine and biology. 1994;21(6):827–34.
11.Choi H, Na KJ. Integrative analysis of imaging and transcriptomic data of the immune landscape associated with tumor metabolism in lung adenocarcinoma: Clinical and prognostic implications. Theranostics. 2018;8(7):1956.
12.Croft D, Mundo AF, Haw R, Milacic M, Weiser J, Wu G, et al. The Reactome pathway knowledgebase. Nucleic acids research. 2013;42(D1):D472-D7.
13.Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462(7269):108.
14.Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC bioinformatics. 2013;14(1):7.
15.Mochizuki T, Tsukamoto E, Kuge Y, Kanegae K, Zhao S, Hikosaka K, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. Journal of Nuclear Medicine. 2001;42(10):1551–5.
16.Kim S, Chung JK, Min HS, Kang JH, Park DJ, Jeong JM, et al. Expression patterns of glucose transporter–1 gene and thyroid specific genes in human papillary thyroid carcinoma. Nuclear medicine and molecular imaging. 2014;48(2):91–7.
17.Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. The Journal of Clinical Endocrinology & Metabolism. 2007;92(7):2840–3.
18.Romei C, Ciampi R, Faviana P, Agate L, Molinaro E, Bottici V, et al. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocrine-related cancer. 2008;15(2):511–20.
19.Choi H, Na KJ. Pan-cancer analysis of tumor metabolic landscape associated with genomic alterations. Molecular cancer. 2018;17(1):150.
20.Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. Journal of cellular physiology. 2005;202(3):654–62.
21.Grabellus F, Nagarajah J, Bockisch A, Schmid KW, Sheu SY. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clinical nuclear medicine. 2012;37(2):121–7.
22.de Geus-Oei L-F, van Krieken JHJ, Aliredjo RP, Krabbe PF, Frielink C, Verhagen AF, et al. Biological correlates of FDG uptake in non-small cell lung cancer. Lung cancer. 2007;55(1):79–87.
23.Meyer HJ, Wienke A, Surov A. Associations between GLUT expression and SUV values derived from FDG-PET in different tumors—A systematic review and meta analysis. PloS one. 2019;14(6):e0217781.
24.Bos R, Van der Hoeven JJ, Van der Wall E, Van der Groep P, Van Diest PJ, Comans EF, et al. Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. Journal of Clinical Oncology. 2002;20(2):379–87.
25.Higashi T, Saga T, Nakamoto Y, Ishimori T, Mamede MH, Wada M, et al. Relationship between retention index in dual-phase 18F-FDG PET, and hexokinase-II and glucose transporter–1 expression in pancreatic cancer. Journal of Nuclear Medicine. 2002;43(2):173–80.
26.Zhao S, Kuge Y, Mochizuki T, Takahashi T, Nakada K, Sato M, et al. Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. Journal of Nuclear Medicine. 2005;46(4):675.
27.HaugenBryan R, AlexanderErik K, BibleKeith C, DohertyGerard M, MandelSusan J, NikiforovYuri E, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016.